drugset / Trial / NCT00821184

Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

NCT00821184

Phase 3 Terminated 12 enrolled Lahey Clinic Astellas Pharma US, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will help determine if behavior modification performed in conjunction with oral Vesicare anticholinergic therapy is more effective for treating overactive bladder symptoms than oral Vesicare anticholinergic therapy alone.

Timeline

Start
2006-09
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Solifenacin Small molecule 5 mg Oral

Indications